{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:01:00Z","timestamp":1785402060076,"version":"3.56.0"},"reference-count":64,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Children with invasive aspergillosis (IA) experience significant morbidity and mortality. Posaconazole is a broad-spectrum triazole antifungal agent indicated for IA treatment in adolescents and adults. A phase 2, open-label, noncomparative, multinational clinical trial in pediatric participants (2-to-&lt;18 years old, body weight \u226510 kg) with possible, probable, or proven IA was conducted. Participants received intravenous posaconazole for \u22651 week, after which they could switch to oral posaconazole for a total treatment duration\n                      <jats:underline>&lt;<\/jats:underline>\n                      12 weeks. Posaconazole dosing and selection of oral formulation (tablet or oral suspension [PFS]) were weight-based. The primary endpoint was safety, assessed as treatment-related adverse events (TRAE) through 14 days after treatment cessation. Global clinical response was a secondary and all-cause mortality an exploratory endpoint. PFS palatability was assessed using a 5-point scale. Thirty-one participants (proven\/probable IA\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 9, possible invasive fungal disease\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 22) received \u22651 dose of posaconazole; 14 were 2 to &lt;12 years, and 17 were 12 to &lt;18 years old. Median treatment duration was 49 (range: 2\u201388) days. Seven participants (22.6%; 95% confidence interval [CI]: 9.6, 41.1) had \u22651 TRAE (grade 1 or 2, all resolved). One participant discontinued treatment due to a nonserious TRAE. Favorable global clinical response rates through weeks 6 and 12 were 67.7% (95% CI: 48.6, 83.3) and 77.4% (95% CI: 58.9, 90.4), respectively (no relapses). Day 114 all-cause mortality was 12.9%. No participants experienced problems taking PFS, and 90.0% rated PFS palatability as very good to neutral. Posaconazole was well tolerated and associated with high clinical response rates in pediatric patients with IA.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>CLINICAL TRIALS<\/jats:title>\n                      <jats:p>\n                        This study is registered with ClinicalTrials.gov as\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04218851\" xlink:type=\"simple\">NCT04218851<\/jats:ext-link>\n                        .\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01305-25","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T14:00:17Z","timestamp":1769522417000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven\/probable invasive aspergillosis or possible invasive fungal disease"],"prefix":"10.1128","volume":"70","author":[{"given":"Hyoung Jin","family":"Kang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04h9pn542","id-type":"ROR","asserted-by":"publisher"}],"name":"Seoul National University College of Medicine","place":["Seoul, Republic of Korea"]},{"id":[{"id":"https:\/\/ror.org\/04h9pn542","id-type":"ROR","asserted-by":"publisher"}],"name":"Seoul National University Cancer Research Institute","place":["Seoul, Republic of Korea"]},{"id":[{"id":"https:\/\/ror.org\/01ks0bt75","id-type":"ROR","asserted-by":"publisher"}],"name":"Seoul National University Children\u2019s Hospital","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-8915","authenticated-orcid":true,"given":"Antonio C.","family":"Arrieta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0282qcz50","id-type":"ROR","asserted-by":"publisher"}],"name":"Children\u2019s Hospital of Orange County","place":["Orange, USA"]},{"id":[{"id":"https:\/\/ror.org\/04gyf1771","id-type":"ROR","asserted-by":"publisher"}],"name":"University of California","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Dhooge","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xmkp704","id-type":"ROR","asserted-by":"publisher"}],"name":"Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Kelemen","sequence":"additional","affiliation":[{"name":"B.-A.Z. V\u00e1rmegyei Central Hospital","place":["Miskolc, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Mac\u00edas-Parra","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05adj5455","id-type":"ROR","asserted-by":"publisher"}],"name":"Instituto Nacional de Pediatr\u00eda","place":["Mexico City, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Aranda","sequence":"additional","affiliation":[{"name":"Hospital Nacional Edgardo Rebagliati Martins","place":["Lima, Peru"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia V.","family":"Dinikina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qepc107","id-type":"ROR","asserted-by":"publisher"}],"name":"Almazov National Medical Research Centre","place":["Saint Petersburg, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Kassis","sequence":"additional","affiliation":[{"name":"Rambam Medical Center","place":["Haifa, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cesaro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00sm8k518","id-type":"ROR","asserted-by":"publisher"}],"name":"Azienda Ospedaliera Universitaria Integrata","place":["Verona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind K.","family":"Shah","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Mackey","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. (author working under contract with Parexel International, Atlanta, GA, USA)","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetty","family":"Waskin","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-1252","authenticated-orcid":true,"given":"Matthew G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.","place":["Rahway, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3401990"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17836.1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101215"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2025.01.002"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-1161"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30723-3"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102393"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107058"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2117"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pix046"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof2020019"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01985-15"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-015-2340-y"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.10.010"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.15702"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad143"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02586-7"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-023-01440-9"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.05.019"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15591"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13654"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy3040210"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13620"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106084"},{"key":"e_1_3_4_28_2","volume-title":"Posaconazole prescribing information","author":"Merck & Co., Inc","year":"2006","unstructured":"Merck & Co., Inc. 2006 (Last revised: October, 2024). Posaconazole prescribing information. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00219-1"},{"key":"e_1_3_4_30_2","unstructured":"Merck & Co. Inc. 2024. E.U. Summary of product characteristics: noxafil 40mg\/ml oral suspension. Rahway NJ USA"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/588660"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1008"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001339"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00484-24"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piu074"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-025-02572-2"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pix030"},{"key":"e_1_3_4_38_2","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. 2022. ICH guideline E11A on pediatric extrapolation. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-guideline-e11a-pediatric-extrapolation-step-2b_en.pdf"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-023-09863-x"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212837"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46328-0"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz741"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00019-17"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa366"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.30699\/ijp.2025.2044324.3369"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00714-4"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof9060674"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00151-6"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix130"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix563"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.152900"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimce.2018.03.021"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13082"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.10.003"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101745"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab1066"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae532"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115473"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab088"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01141-23"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-023-00459-z"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1159\/000547799"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2850"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01305-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01305-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T14:00:51Z","timestamp":1772632851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01305-25"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1128\/aac.01305-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01305-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"2025-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01305-25"}}